Skip to content

Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar

Controlled Trial of Risperidone and Divalproex Sodium With MRI Assessment of Affected Circuitry in Pre and Post Treatment in Pediatric Bipolar

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00176202
Enrollment
65
Registered
2005-09-15
Start date
2003-04-30
Completion date
2008-01-31
Last updated
2015-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder

Brief summary

The study is to examine the null hypothesis that risperidone and divalproex sodium are equally effective in treating/stabilizing pediatric bipolar disorder.

Detailed description

Pediatric Bipolar Disorder (PBD) severely impairs a child's emotional development, and is associated with alarming rates of suicide, school failure, aggression, risk taking behaviors and substance abuse (Geller et al, 1998; 2001; Carlson et al, 1998). At present, very little is known about the pathophysiology or optimal treatment of PBD. The long range goals of this proposal are threefold: to investigate a range of pharmacotherapeutic agents that are safe and efficacious for PBD, to use fMRI techniques to examine abnormalities in brain function in this disorder, as well as any change in brain function after treatment. In contrast to the adult literature, we are aware of only two prospective studies assessing the efficacy of standard mood stabilizers in a pediatric sample. In one, lithium was found to be moderately effective in PBD with comorbid substance abuse (Geller et al, 1998). In the other, divalproex sodium, lithium and carbamazepine produced a maximum of 50% symptom reduction (Kowatch et al, 2000). Subsequently, Kafantaris et al (2001) observed a potentiation of lithium's antimanic effect when combined with risperidone. Further, a prospective, open trial of olanzapine for PBD reported a 70% symptom reduction (Frazier et al, 2001) with a retention rate of 96% compared to only 7% with classic mood stabilizers (Kowatch et al, 2000). Thus, parallelling adult studies (Sachs et al, 2000), novel antipsychotics are a promising treatment in this population. Further, up to 60% of acute PBD episodes present with psychotic features (Geller et al, in press). Finally, the time to full effect with mood stabilizers is often 4 weeks in children (Kowatch et al, 2000; Geller et al, 1998; Kafantaris et al, 2001), whereas antipsychotics usually have a more rapid response onset (Pavuluri et al, in press). Given the potential efficacy of novel antipsychotics for PBD, the aim is to conduct a randomized trial comparing a novel antipsychotic to a standard mood stabilizer:

Interventions

DRUGDivalproex Sodium

Divalproex sodium is a mood stabilizer

DRUGrisperidone

Risperidone is a second generation antipsychotic and antimanic drug

Sponsors

University of Illinois at Chicago
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
10 Years to 20 Years
Healthy volunteers
No

Inclusion criteria

* Children with Bipolar Disorder * Must be able to swallow tablets

Exclusion criteria

* Children with general medical condition such as head injury, epilepsy, endocrine disorders * Those who are on mood altering medications such as steroids, and those diagnosed with mental retardation are excluded to avoid confounding and contributing factors to mood swings. * If we discover during the interview that the parent and/or child does not understand the consent/assent procedures, we will exclude them. We expect only a small number of children to be excluded from the study due to exclusionary criteria. Selection of the subjects is not based on sex, race, or ethnic group.

Design outcomes

Primary

MeasureTime frameDescription
Young Mania Rating Scale (YMRS)Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).This measure has 11 items. The purpose of each item is to rate the severity of that abnormality in the patient. A severity rating is assigned to each of the eleven items, based on the patient's subjective report of his or her condition over the previous forty-eight hours and the clinician's behavioral observations during the interview, with the emphasis on the latter. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. Total score of zero to 60 is possible, zero being normal and 60 being severe, 12 serving as a cut off point for illness if equal or above. There are several ways to show change in outcome. We show the mean and standard deviation at week 0 and 6.

Secondary

MeasureTime frameDescription
Child Depression Rating Scale- Revised (CDRS-R)Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).Response for depressive symptoms was defined as a score less than 40 on the CDRS-R. Range is 18 to 120. Score 18 is normal and higher score signifies depression. The Children's Depression Rating Scale (CDRS) is a 16-item measure used to determine the severity of depression in children 6-18 years of age. Items are measured on 3-, 4-, 5-, and 6-point scales. The mean and standard deviation are measured in this study to illustrate outcome at baseline and when the subject ended the study.
Child Mania Rating Scale (CMRS)Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).Child Mania rating scale is a parent rated measure to screen for symptoms of mania. It includes 21 items reflecting the DSM-IV criteria for a manic episode. Each item is answered on a four-point Likert type scale anchored by 0 (Never/Rare), 1 (Sometimes), 2 (Often), and 3 (Very Often). Maximum score possible is 63. Score higher than 20 is considered clinically significant, and this is a dimensional score of manic severity.
Clinical Global Improvement in Bipolar Disorder Overall (CGI-BP Overall)Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).Severity of Illness and Global Improvement are rated on a 7-point scale by the clinician. In addition to rating the overall illness with the CGI-BP, severity and improvement are considered on various other dimensions such as mania, depression, attention deficit/hyperactivity, psychosis, aggression and sleep difficulties. Score of 1, 2 and 3 would mean there is clinically observed symptom improvement where 1 is the best outcome than 2 or 3. The point 4 is the point where the subject presents at baseline of that specific individual. If they become worse on clinical symptoms, they are rated as 5, 6 or 7 where 7 is worse than 5.

Countries

United States

Participant flow

Recruitment details

Dates of recruitment :From Sep2005 - Jan 2008.in Clinic Subjects enrolled:65

Pre-assignment details

Exclusion Criteria: * Children with general medical condition such as head injury, epilepsy, endocrine disorders * Those who are on mood altering medications such as steroids, and those diagnosed with mental retardation are excluded to avoid confounding and contributing factors to mood swings.

Participants by arm

ArmCount
Risperidone
Risperidone is an antipsychotic medication and is used to treat mania. Its trade name is Risperdal. Aim of the study is to cross compare the relative efficacy and safety of risperidone and divalproex sodium in treating/stabilizing mania in pediatric bipolar disorder.
32
Divalproex
Divalproex sodium, also referred to as divalproex is an antiepileptic medication used for mania and is referred to as mood stabilizer. Its trade name is Depakote.
33
Total65

Baseline characteristics

CharacteristicRisperidoneDivalproexTotal
Age, Continuous10.47 years
STANDARD_DEVIATION 3.18
11.23 years
STANDARD_DEVIATION 3.5
10.85 years
STANDARD_DEVIATION 3.34
Region of Enrollment
United States
32 participants33 participants65 participants
Sex: Female, Male
Female
12 Participants14 Participants26 Participants
Sex: Female, Male
Male
20 Participants19 Participants39 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
8 / 3210 / 33
serious
Total, serious adverse events
0 / 320 / 33

Outcome results

Primary

Young Mania Rating Scale (YMRS)

This measure has 11 items. The purpose of each item is to rate the severity of that abnormality in the patient. A severity rating is assigned to each of the eleven items, based on the patient's subjective report of his or her condition over the previous forty-eight hours and the clinician's behavioral observations during the interview, with the emphasis on the latter. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. Total score of zero to 60 is possible, zero being normal and 60 being severe, 12 serving as a cut off point for illness if equal or above. There are several ways to show change in outcome. We show the mean and standard deviation at week 0 and 6.

Time frame: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).

Population: Inclusion criteria were a DSM-IV diagnosis of bipolar disorder Type I (mixed or manic episode); 8 to 18 years old; and medication free or currently clinically unstable on medication, justifying termination of the ineffective regimen.

ArmMeasureGroupValue (MEAN)Dispersion
DivalproexYoung Mania Rating Scale (YMRS)Baseline25.09 units on a scaleStandard Deviation 7.51
DivalproexYoung Mania Rating Scale (YMRS)Last observation carried forward (LOCF)15.24 units on a scaleStandard Deviation 12.49
RisperidoneYoung Mania Rating Scale (YMRS)Baseline30.59 units on a scaleStandard Deviation 7.04
RisperidoneYoung Mania Rating Scale (YMRS)Last observation carried forward (LOCF)10.22 units on a scaleStandard Deviation 10.5
p-value: <0.01Chi-squared
p-value: <0.01Chi-squared
Secondary

Child Depression Rating Scale- Revised (CDRS-R)

Response for depressive symptoms was defined as a score less than 40 on the CDRS-R. Range is 18 to 120. Score 18 is normal and higher score signifies depression. The Children's Depression Rating Scale (CDRS) is a 16-item measure used to determine the severity of depression in children 6-18 years of age. Items are measured on 3-, 4-, 5-, and 6-point scales. The mean and standard deviation are measured in this study to illustrate outcome at baseline and when the subject ended the study.

Time frame: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).

ArmMeasureGroupValue (MEAN)Dispersion
DivalproexChild Depression Rating Scale- Revised (CDRS-R)Baseline40.76 units on a scaleStandard Deviation 13.34
DivalproexChild Depression Rating Scale- Revised (CDRS-R)Last Observation Carried Forward (p<.01)35.76 units on a scaleStandard Deviation 15.01
RisperidoneChild Depression Rating Scale- Revised (CDRS-R)Baseline41.72 units on a scaleStandard Deviation 17.44
RisperidoneChild Depression Rating Scale- Revised (CDRS-R)Last Observation Carried Forward (p<.01)25.88 units on a scaleStandard Deviation 9.13
p-value: <0.01Chi-squared
p-value: 0.01Chi-squared
Secondary

Child Mania Rating Scale (CMRS)

Child Mania rating scale is a parent rated measure to screen for symptoms of mania. It includes 21 items reflecting the DSM-IV criteria for a manic episode. Each item is answered on a four-point Likert type scale anchored by 0 (Never/Rare), 1 (Sometimes), 2 (Often), and 3 (Very Often). Maximum score possible is 63. Score higher than 20 is considered clinically significant, and this is a dimensional score of manic severity.

Time frame: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).

ArmMeasureGroupValue (MEAN)Dispersion
DivalproexChild Mania Rating Scale (CMRS)Baseline30.84 units on scaleStandard Deviation 10.87
DivalproexChild Mania Rating Scale (CMRS)LOCF16.35 units on scaleStandard Deviation 13.09
RisperidoneChild Mania Rating Scale (CMRS)LOCF19.20 units on scaleStandard Deviation 12.66
RisperidoneChild Mania Rating Scale (CMRS)Baseline28.0 units on scaleStandard Deviation 9.02
p-value: <0.01Chi-squared
p-value: <0.01Chi-squared
Secondary

Clinical Global Improvement in Bipolar Disorder Overall (CGI-BP Overall)

Severity of Illness and Global Improvement are rated on a 7-point scale by the clinician. In addition to rating the overall illness with the CGI-BP, severity and improvement are considered on various other dimensions such as mania, depression, attention deficit/hyperactivity, psychosis, aggression and sleep difficulties. Score of 1, 2 and 3 would mean there is clinically observed symptom improvement where 1 is the best outcome than 2 or 3. The point 4 is the point where the subject presents at baseline of that specific individual. If they become worse on clinical symptoms, they are rated as 5, 6 or 7 where 7 is worse than 5.

Time frame: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).

ArmMeasureGroupValue (MEAN)Dispersion
DivalproexClinical Global Improvement in Bipolar Disorder Overall (CGI-BP Overall)Baseline4.80 units on a scaleStandard Deviation 1.06
DivalproexClinical Global Improvement in Bipolar Disorder Overall (CGI-BP Overall)LOCF2.77 units on a scaleStandard Deviation 1.28
RisperidoneClinical Global Improvement in Bipolar Disorder Overall (CGI-BP Overall)Baseline4.37 units on a scaleStandard Deviation 0.67
RisperidoneClinical Global Improvement in Bipolar Disorder Overall (CGI-BP Overall)LOCF2.97 units on a scaleStandard Deviation 1.5
Comparison: baseline is compared to LOCF to determine the p value.p-value: <0.01Chi-squared
p-value: <0.01Chi-squared

Source: ClinicalTrials.gov · Data processed: Mar 27, 2026